FLT201

About Spur Therapeutics

Spur Therapeutics is a UK-based, clinical-stage biotech pioneering optimized gene therapies. Its lead candidate, FLT201, is an AAV gene therapy for Type 1 Gaucher disease, with promising two-year Phase 1/2 data presented in 2026. The company's strategy involves leveraging its platform to expand from rare diseases into larger indications like Parkinson's, dementia, and cardiovascular conditions, aiming for transformational, one-time treatments.

Therapeutic Areas